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Each dry powder inhaler has a dierent resistance so that a respirable dose can be generated from the formulation
by the patient’s inspiratory eort. It is important to recognize that this eect is achievable. The inspiratory flow
characteristics of asthmatics inhaling through a Clickhaler1 were determined. In a separate study 10 volunteers
inhaled separate 26100 g salbutamol doses from a Clickhaler (ML Laboratories plc U.K.). Two dierent
formulations (one with a high and one with a low respirable fraction) were each inhaled using an inspiratory flow of
30 and 60 l min71. A urine sample was collected 30 min post inhalation and then pooled for the next 24 h. The
mean (SD) inhalation rate of 24 asthmatics when they inhaled from a Clickhaler was 373 (146) l min71. The mean
(SD) urinary salbutamol excretion during the first 30 min, by the volunteers, using the high respirable dose
formulation at 30 and 60 l min71 was 559(187) and 462 (149) g respectively (P5001). Similar values using the
low respirable dose formulation were 484 (158) and 386 (214) g. There was no significant dierence between the
amounts excreted in the 24 h post-dose. The dierent 30-min urinary excretions following inhalation of the two
formulations suggest a link between the relative bioavailability of salbutamol to the lung and the respirable dose,
and that a slow inhalation rate should be used when using a Clickhaler. The patient study shows that this rate is
achieved by most asthmatics without further training.
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In the past the metered dose inhaler (MDI) has been the
inhalation device of choice for the delivery of drugs to the
lungs. Recently, the importance and use of dry powder
inhalers (DPI) has gained momentum in line with the
phasing out of the chlorofluorocarbon propellants used in
the formulation of MDIs. All these dry powder devices rely
on the patient’s inspiration to generate the energy required
to deliver a dose with particles in the respirable range. To
facilitate this process some DPIs (especially those from
which the formulation is metered from a reservoir) are
designed with a moderate to high internal resistance. Thus,
inspiration through these is not as easy as when using an
MDI which has negligible resistance.
Recently, studies have shown that lung deposition and
the fine particle dose of those DPIs with moderate to high
resistance are inspiration rate-limited. Newman et al. (1)
have shown that the mean (SD) total lung deposition of
radiolabelled terbutaline in 10 asthmatics, from a Turbo-
haler1 (Astra Draco, Sweden), using inspiration rates ofPaper received 22 February 1999 and accepted 18 May 1999.
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0954-6111/00/010051+06 $35?00/0approximately 60 and 30 l min71 was 168 (82) and 91
(47)% of the inhaled dose. Spirometry revealed that there
was more bronchodilation using the fast rate but the
dierences did not reach statistical significance. Similar
results have been reported using a pulvinal1 (Chiesi, Italy)
dry powder inhaler in that the mean (SD) total lung
deposition using a fast and slow inspiration rate was 161
(32) and 117 (23)% of the inhaled dose (2). These two
studies used gamma scintigraphy. An alternative method to
quantify the lung dose is urinary drug excretion with oral
charcoal to block gastrointestinal absorption (3,4). Using
this method the total lung dose of salbutamol from a
Turbohaler1 and a Cyclohaler1 (Pharbita, Italy) have both
been shown to be greater when inhaling with a higher
inspiratory eort (4). These studies, therefore, highlight the
importance of counselling patients that they should inhale
with a forced suck. An inhalation rate of 60 l min71
through their DPI may be dicult to achieve for patients
with asthma and by those with chronic obstructive airways
disease, especially if the DPI has a high resistance to
airflow. A recent study has highlighted this latter comment
in that less than 20% of asthmatics attending an outpatient
clinic achieved an inhalation rate of 60 l min71 or more
when using a Turbohaler (6).
The Cyclohaler and Turbohaler study (4) also used in
vitromethods to measure the fine particle dose and reported# 2000 HARCOURT PUBLISHERS LTD
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dose. Using in vitro methods, the potential of a reduced
total lung dose with lower inspiratory flow for the
Turbohaler has been reported by others (7,8). It is
important, therefore, that for DPIs with a moderate to
high resistance, studies are carried out to evaluate the eect
of inspiration rate on lung deposition and also that patients
can achieve these rates. We have therefore carried out such
studies for a new DPI (Clickhaler, ML Laboratories plc,
U.K. now marketed as Asmasal by Medeva Ltd., U.K.).
The delivery of drug to the lung has been compared at two
inspiration rates using urinary excretion of salbutamol. We
have also used this method to investigate the eect of
formulation changes on the fine particle dose emitted from
this device. To compare relative lung deposition the amount
of salbutamol excreted in the urine during the first 30 min
post-inhalation has been used. This represents the relative
bioavailability of salbutamol to the lungs and is an index
which can be used to compare the total lung dose of two
inhaled products/methods (9). The total amount of
salbutamol and its metabolite excreted in the urine over
the 24-h period post-inhalation represents the relative
bioavailability of salbutamol to the body and has been
used to compare the total drug dose emitted and delivered
to the body from two inhaled products/methods.
Methods
STUDY 1
The inhalation rate profiles of asthmatic patients [forced
expiratory volume in 1 sec (FEV1)585% predicted]
attending an out patient clinic were measured when they
inhaled through the Clickhaler. This study was approved by
the local Research Ethics Committee, and all patients gave
written informed consent. Following measurement of
baseline spirometry, all patients were asked to inhale from
a placebo Clickhaler using their normal inhalation techni-
que. Thus, no counselling was given to each patient.
The placebo Clickhaler used in this study was fitted with
a probe at the mouth-piece to record pressure changes
during inspiration. In vitro studies of flow via pressure drop
measurements at the mouth-piece of the placebo Clickhaler
were made to determine the resistance in the device (5). The
pressure changes during each inhalation by the patient at
02, 04, 06, 08, 10, 12, 14 and 20 sec post-inhalation,
through the adapted Clickhaler were captured electroni-
cally using a Quattro Pro1 (Corel, USA) spreadsheet.
These values were transformed to inhalation rates and then
volumes, via the in vitro determined resistance of the
adapted inhaler by the method recommended by Clark and
Hollingworth (5). The better of two inhalations was
recorded. Each subject was then counselled about inhala-
tion technique and informed to inhale with a forced suck.
The inhalations were again recorded.
STUDY 2
Healthy volunteers (aged 4 18 years) gave written
informed consent to participate in the study. The studywas approved by the Ethics Committee of the University of
Bradford. All subjects were experienced in inhaler techni-
que in order to reduce intra-subject variability.
Each subject completed four 24-h study periods which
were each separated by at least six full days. At the start of
each study period subjects inhaled 26100 g of salbutamol
(nominal dose 200 g) via a Clickhaler (now marketed as
Asmasal, Medeva Ltd., U.K.). Salbutamol was inhaled
from the Clickhaler as four dierent study treatments; at an
inspiratory flow rate of 30 l min71 and 60 l min71 for two
formulations (A and B) in a randomized four-way cross-
over design. For formulation A the mean (SD) fine particle
dose, otherwise known as the respirable fraction, deposited
into stage 2 of a twin stage impinger was 253 (14)% (low in
vitro respirable dose) and for formulation B this value was
38 (26)% (high in vitro respirable dose). The twin stage
impinger was Apparatus B as recommended by the British
Pharmacopoeia, Appendix XVIII. Using this method the
fraction captured in stage 2 represents the particles 564
m from each emitted dose. The study was blind with
respect to the formulation, but was open with respect to the
eect of flow rate.
Subjects emptied their bladders immediately before each
drug administration and then urine samples were collected
at 30 min and subsequently pooled until 24 h after the
treatment. The volume of urine passed was recorded and
samples were stored at7208C before analysis. A previously
validated, sensitive high performance liquid chromatogra-
phy (HPLC) method was used to measure urine concentra-
tions of salbutamol and its metabolite, the sulphate ester
conjugate (9).
Subjects did not drink alcohol or caeine-containing
beverages for 12 h before or 24 h after treatment. Vital signs
(heart rate and diastolic blood pressure) were recorded pre-
treatment and at 5, 10, 20, 30 and 60 min post-treatment.
Adverse eects experienced by the subjects were recorded.
Inspiratory flow rates and inspired volumes were recorded
for each inhaled dose.
Analysis of variance (ANOVA) was undertaken to
compare the dierent formulations and flow rates, and
the mean dierence (95% confidence safe interval) was
calculated for each comparison.
Results
STUDY 1
Twenty-four patients (13 females) whose mean (SD) age was
530 (153) years had their inhalation rate profiles measured
when inhaling with the Clickhaler. Their mean (SD) FEV1
forced vital capacity (FVC) and peak expiratory flow rate
(PEFR) was 20 (11) l, 26 (11) l and 288 (169) l min71
respectively. Figure 1 shows that the inspiration flows were
greater after counselling than the patients’ normal techni-
que. The mean (SD) peak inhalation rate was 373 (146) l
min71 before counselling and 4693 (165) l min71
following counselling. The range for the inhalation rates
prior to counselling was 176 to 695 l min71 and after
counselling was 193 to 724 l min71. The mode time at
Fig. 1. Mean (SD) inhalation flow rates through a
Clickhaler1 by 24 asthmatic patients. -&- :pre-
counselling; -*- post-counselling.
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the start of the inhalation for both normal and forced
manoeuvres. There was no dierence in the total volume
inhaled pre- and post-counselling with a mean (SD) of 113
(016) and 113 (020) l respectively.
STUDY 2
Twelve (seven female) volunteers completed this study.
Their mean (SD) age, weight and height was 345 (108)
years, 704 (138) kg and 1715 (119) cm, respectively. The
mean (SD) inhalation rate for slow and first inhalations was
294 (694) and 591 (199) l min71 respectively and the
volumes inhaled were 241 (057) and 249 (061) l
respectively. The mean (SD) amounts of salbutamol excreted
in the urine during the first 30 min after their inhalations
are shown in Table 1 together with the total amounts of
salbutamol and its metabolites excreted in the 24-h period
post-inhalation.
THE EFFECT OF INSPIRATORY FLOW RATE
Table 1 and Fig. 2(a) shows that for formulation A the
amount of salbutamol excreted in the urine during the firstTABLE 1. Mean (SD) salbutamol (g) recovered in urine at 30
inhatation
Urinary salbutamol
variable
Formulation A
(‘low twin impinge
30 l min71 6
Salbutamol (g)
30 min post-inhalation
484 (158) 3
Salbutamol and its
metabolites (g)
24 h post-inhalation
929 (283) 7
n12 for all values30 min after inhalation was greater for the slow inhalation
than the fast inhalation. However, the dierences were not
significant with a mean dierence (95%) confidence interval
(CI) of 098 (7027, 223) g. Table 1 and Fig. 2(b) reveal
similar results for formulation B, but on this occasion the
dierence was significant (P5001) in favour of the slow
inhalation, with a mean dierence (95% CI) of 096 (014,
179) g. When the data for both formulations A and B
were combined, the urinary excretion of salbutamol in the
30 min post-inhalation was significantly greater (P5001)
for the slow inhalation than the fast inhalation with mean
(SD) of 521 (173) and 424 (185) g respectively, and mean
dierence (95% CI) of 0.97 (026, 160) g.
Although Table 1 indicates that the total amount of
salbutamol and its metabolite excreted over the 24-h period
dose was lower for the fast inhalation using formulation A,
statistical analysis showed no dierence. The mean
dierence (95% CI) for slow and fast inhalation using
formulation A was 143 (759, 345) g and for formula-
tion B was 12 (7235, 217) g.
THE EFFECT OF IN VITRO PARTICLE SIZE
DISTRIBUTION
Comparison of formulation A and B in Fig. 3(a) and 3(b)
respectively, and the summary in Table 1, shows that the
amount of salbutamol excreted in the urine in the first 30
min post-inhalation was greater for formulation B than A
when using either a slow or a fast inhalation rate. When the
30 min urinary salbutamol excretion for all inhalations of
formulation B were combined and compared to those of
formulation A the mean dierence (95% CI) was 077 (145,
008) g (P5005).
Comparison of the total excretion of salbutamol and its
metabolite (summarized in Table 1) in the 24-h period post-
inhaled dosing revealed no dierence between the two
formulations when using a low inhalation rate. The mean
dierent (95% CI) between formulations B and A was 36
(7252, 327) g. similar comparison between formulations
A and B for the fast inhalation rate showed that
significantly more (P5005) salbutamol and its metabolites
were excreted following formulation B with a mean
dierence (95% CI) of 1673 (20, 353) g.min and 24 h (salbutamaol plus metobolized drug) post-
r’)
Formulation B
(‘high twin impinger’)
0 l min71 30 l min71 60 l min71
86 (214) 559 (187) 462 (149)
85 (286) 964 (313) 953 (236)
Fig. 2. Mean (SD) and individual urinary excretion of
salbutamol during the first 30 min post-inhalation using a
slow and fast inhalation rate for (a) formulation A and (b)
formulation B.
Fig. 3. Mean (SD) and individual urinary excretion of
salbutamol during the first 30 min post-inhalation for
formulation A and B using (a) slow and (b) fast inhalation
rate.
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Following each inhalation there were no clinically signifi-
cant changes in heart rate or systolic/diastolic blood
pressure. There were no reported adverse events and no
subjects withdrew from the study.
Discussion and conclusions
Previous studies for DPIs with a moderate to high
resistance have revealed lung deposition with a higher
inspiratory flow rate (1,2,4). In vitro assessment has shown
that the emitted dose from a Turbohaler is dose-dependent
(7,8). This could be due to the energy required to
deaggregate the drug within the formulation to provide
the respirable fraction. A recent study using a new
multidoses DPI—the Spiros (Dura Pharmaceuticals,
U.S.A.)—has shown that a greater amount of drug was
deposited in the lung for the lowest flow rate studied (10).
The Spiros deaggregates the respirable drug powder bybattery power within the device and thus does not require
inspiratory energy to produce the respirable dose. This
suggests that our results indicate that less inspiratory eort
is necessary to deaggregate the micronized salbutamol from
the lactose excipient of the formulation in the Clickhaler.
Thus, it seems that the total lung delivery from dry powder
inhalers varies with inspiratory rate. It is important,
therefore, that these studies are carried out for all DPIs
such that patient information leaflets contain the necessary
information instead of the general rule that when inhaling
from a DPI no counselling is necessary.
One problem for gamma scintigraphy when determining
lung deposition is that it does not dierentiate between the
amount of drug delivery to the lungs which is cleared by
mucociliary clearance and absorbed through the ariway
walls into the systemic circulation. For bronchodilator and
anit-inflammatory eects it is drug cleared by the latter
route which will exert a clinical eect. The anomaly
between urinary pharmacokinetics (which identifies drug
cleared from the lungs by absorption into the system
circulation) and gamma scintigraphy was shown in a study
comparing two methods at dierent inhalation rates (11).
When terbutaline was inhaled from a metered dose inhaler
A DRY POWDER INHALER AND SALBUTAMOL BIOAVAILABILITY 55at 30 l min71 there was no dierence in the total lung dose
between the two methods. When a rate of 180 l min71 was
used the urinary method showed significantly less total lung
deposition than gamma scintigraphy. At this faster
inspiration rate the gamma scintigraphy results show that
more was deposited into the central lung zone and less in
the peripheral lung zone. The results from gamma
scintigraphy studies which show greater lung deposition
at higher flow rates for dry powder devices such as the
Turbohaler will be aected by this phenomena. However,
urinary excretion studies using the Turbohaler (4) have also
indicated greater lung deposition at higher inspiration rates.
The in vitro results (7,8) showing that dose emission from a
Turbohaler is flow-dependent would explain the urinary
data. Care should therefore be used when comparing total
lung deposition measured by dierent techniques, especially
for gamma scintigraphy which over-estimates the eective
lung dose. Comparison of urinary excretion data does
indicate that for the Turbohaler a hard suck should be used
whereas this study indicates that a slow inspiration rate is
the best for the Clickhaler.
Our in vitro tests have shown that the Clickhaler has a
similar resistance to that of a Turbohaler. The urinary
salbutamol 30-min data reveals that when using an
inhalation of 30 l min71 there is a higher relative bioavail-
ability of salbutamol to the lung than at 60 l min71. The
asthma patient study reveals that when using a normal
inhalation with counselling the mean (SD) inhalation rate
was 373 (146) l min71 and thus the optimal flow is
achievable. This is in contrast to the Turbohaler in that
more than 80% of patients attending an outpatient clinic
could not achieve the optimal inspiratory flow-rate of
60 l min71 (6) indicated by lung deposition studies (1,4).
There is growing evidence of a link between the in vitro
measurement of the fine particle dose and in vivo total lung
deposition (4,12,13). This is backed up by the greater
urinary excretion of salbutamol following inhalation of
formulation B compared to formulation A. It is important,
therefore, that in vitro particle size analysis data is
presented for all DPIs using dierent flow rates.
Although we have only measured the respirable fraction
using the twin-stage impinger rather than the particle size
distribution, the above comments are valid. Zanen et al.
used monosized salbutamol particles emitted from metered
dose inhaler which were inhaled by asthmatic patients
(14,15). They used sizes of 1, 28 and 5 m and compared
them to placebo. They showed that the optimal response
was obtained from particles sized 28 m. These would have
delivered more drug to the lungs than the 5 m formulation
and is consistent with the reports mentioned above, (12,13)
in that total lung deposition is more important than
regional deposition. For particles51 m the Zanen studies
showed less response because there would nave been more
delivered to the alveoli where there is no smooth muscle for
bronchodilation. This could still be the reason for increased
amounts of salbutamol excreted in the urine within the first
30 min for formulation B. However, we have recently
completed a study which has shown a correlation between
our 30-min urinary salbutamol excretion method and
provocational dose causing a 20% fall in FEV, (PD20)using 12 asthmatics (16). This indicates that this urinary
excretion index is related to the eective bronchodilator
lung dose rather than dierent deposition into regions of
the lung.
The study highlights the value of the 30-min urinary
salbutamol measurement to provide an index of total lung
deposition to compare dierent inhaled products, inhala-
tion rates and formulations. Some studies (4) have
advocated the use of oral charcoal to prevent the
gastrointestinal absorption of salbutamol but one of our
recent studies has shown that this is not necessary (17).
Although the urinary method only gives an indication of
total lung deposition rather than the distribution of drug
within the lungs, the literature indicates that for b-agonists
it is the total lung dose which correlates most closely to the
clinical eect (15). We now have data to demonstrate a link
between the 30 min urinary excretion of salbutamol to
pharmacodynamic endpoints (methacholine challenge) in
asthmatic subjects (16). The urinary method highlights the
eective lung dose and uses products available to the
patient, is non-invasive and simple. This, together with its
ability to highlight relatively small changes (in lung
deposition) indicates the value of this technique to
demonstrate the therapeutic equivalence between inhaled
products and/or inhalation methods.
Acknowledgement
This study was supported by ML Laboratories, St. Alban’s,
Hertfordshire.
References
1. Newman SP, Moren F, Trufust E, et al. Terbutaline
sulphate Turbuhaler: eect of inhaled flow rate on drug
deposition and ecacy. Int J Pharm 1991; 74: 209–213.
2. Pitcairn C, Lunghetti G, Venture P et al. A Compar-
ison of the lung deposition of salbutamol inhaled from
a new dry powder inhaler at two inhaled flow rates. Int
J Pharm 1994; 102: 11–18.
3. Borgstro¨m L, Nilsson M, A method for the determina-
tion of the absolute pulmonary bioavailability of
inhaled drugs: Terbutaline. Pharm Res 1990; 7:
1068–1070.
4. Olsson B, Asking L, Borgstro¨m L et al. Eect of inlet
throat on the correlation between fine particle dose and
lung deposition, In: Dalby RN, Byron PR, Farr ST,
eds. Respiratory Drug Delivery V, Phoenix, USA:
Interpharm Press 1996; 273–281.
5. Clark AR, Hollingworth AM. The relationship be-
tween powder inhaler resistance and peak inspiratory
conditions in healthy volunteers — implications for in
vitro testing. J. Aerosol Med 1993; 6: 99–110
6. Johnson S, Miles JF, Weir DC et al. Turbohaler:
objective assessment of patient generated flow Thorax
1996; 51(Suppl. 3): A75.
56 J. K. CHEGE AND H. CHRYSTYN7. Malton A, Symby BS, Smith IJ. A comparison
of in vitro drug delivery from two multidose
powder inhalation devices. Eur J Clin Res 1995; 7:
177–193.
8. Malton A, Sumby BS, Dandiker T. A comparison of in
vitro drug delivery from salbutamol Diskus and
terbutaline Turbohaler inhalers. J Pharm Med 1996;
6: 35–48.
9. Hindle M, Chrystyn H. Determination of the rela-
tive bioavailability of salbutamol to the lung follow-
ing inhalation. Brit J clin Pharmacol 1992; 34:
311–315.
10. Dolovich M, Them R. Small dierences in inspiratory
flow rate (IFR) and aerosal particle size can influence
upper and lower respiratory trace deposition. J Aerosol
Med 1997; 20: 238.
11. Newman S, Stead K, Hooper G et al. Comparison of
gamma scintigraphy and a pharmacokinetic technique
for assessing pulmonary deposition of terbutaline
sulphate delivery by pressurized metered dose inhaler.
Pharm Res 1995; 12: 231–236.
12. Zainudin BMZ, Biddescombe M, Tolfree SEJ et al.
Comparison of bronchodilator responses and deposi-
tion patterns of salbutamol inhaled from pressurisedmetered dose inhaler, as a dry powder inhaler and as a
nebulised solution. Thorax 1990; 45: 469–473.
13. Chrystyn H. Key factors in drug delivery to the lungs
(in press).
14. Zanen P, Go TL, Lammers J-WJ. Optimal particle size
for 2-agonists and anticholinergic aerosols in patients
with severe airflow destruction. Thorax 1996; 51:
977–980.
15. Zanen P, Go TL, Lammers J-WJ. The optimal particle
size for 2-adrenergic aerosols in mild asthmatics. Int J
Pharm 1994; 101: 211–217.
16. Chrystyn H, Allen MD, corlett SA et al. Simultaneous
measurement of pharmacodynamic and pharmacoki-
netic parameters which can be used to evaluate the
equivalence of inhaled salbutamol. Am Rev Resp Crit
Care Med 1998; 157: A636.
17. Chrystyn H, Corlett SA, Tomlinson HS. Further
validation on the use of urinary salbutamol excretion
to evaluate the relative bioavailability of salbutamol to
the lung following inhalation. Thorax 1997; 52
(Suppl.6): A82.
18. Chrystyn H. Is total particle dose more important than
particle distribution? Respir Med 1997; 91(Suppl.A):
17–19.
